ParaPRO LLC
11
0
0
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
45%
5 trials in Phase 3/4
45%
5 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies
Role: lead
Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies
Role: lead
A Pilot Dose Ranging Study of Spinosad Creme Rinse
Role: lead
Pharmacokinetic (PK) and Tolerance Study of Natroba Topical Suspension in Pediatrics With an Active Head Lice Infestation
Role: lead
Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice
Role: lead
Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice
Role: lead
A Safety and Efficacy Pilot Study Comparing NatrOVA Creme Rinse 1% and NIX Creme Rinse
Role: lead
NatrOVA Photoallergy Study - NatrOVA Creme Rinse in Healthy Volunteers
Role: lead
A Pharmacokinetic (PK) Study of NatrOVA Topical Creme (1%) in Pediatric Subjects 6 to 24 Months of Age
Role: lead
Phototoxicity Potential of NatrOVA Creme Rinse - 1%
Role: lead
A Dose Ranging Study of Different Strengths of Spinosad Topical Creme in Subjects With Pediculosis Capitis
Role: lead
All 11 trials loaded